158392-80-4

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-tert-butyl 2-ethyl 4,4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate is used as a potential pharmaceutical intermediate for the synthesis of various drugs. Its unique structure and chiral center may contribute to the development of new therapeutic agents with specific biological activities.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-1-tert-butyl 2-ethyl 4,4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate can be utilized as a building block or a reagent in the synthesis of complex organic molecules. Its dicarboxylate ester and pyrrolidine ring functionalities may facilitate the formation of new chemical entities with desired properties.
Used in Materials Science:
(S)-1-tert-butyl 2-ethyl 4,4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate may also find applications in materials science, where its unique structure could be employed to develop new materials with specific properties. For instance, it could be used in the synthesis of polymers, coatings, or other materials with tailored characteristics.

Upstream product

• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 74-88-4 methyl iodide 
• 98-79-3 L-Pyroglutamic acid 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 151139-88-7 4,4-dimethyl-L-glutamic acid 
• 1001353-88-3 1-tert-butyl 2-ethyl 2,4,4-trimethyl-5-oxopyrrolidine-1,2-dicarboxylate 
• 212890-85-2 (S)-(+)-(4,4-dimethylpyrrolidin-2-yl)methan-1-ol 
• 212890-86-3 (S)-(-)-tert-butyl 2-(hydroxymethyl)-4,4-dimethylpyrrolidinecarboxylate 
• 189098-09-7 (2S)ethyl N-[2R,3R-(3-hydroxy-2-methyl-3-phenylpropionyl)]-4,4-dimethylpyroglutamate 

Relevant academic research and scientific papers

POLYMYXIN ANALOGS USEFUL AS ANTIBIOTIC POTENTIATORS

The disclosure provides compounds of the formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of either of the foregoing. The variables A, R1, and R2 are defined in the disclosure. The disclosure further includes pharmaceutical compositions comprising a compound of formula I together with at least one pharmaceutically acceptable carrier. The disclosure also includes a method of sensitizing bacteria to an antibacterial agent, comprising administering to a patient infected with the bacteria, simultaneously or sequentially, a therapeutically effective amount of the antibacterial agent and a compound of formula (I).

TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION

Tetracyclic heterocycle compounds of formula (I) and pharmaceutically acceptable salts thereof are provided, wherein A, A', G, R1, R15, U, V, V', W, W, X, X', Y and Y' are as defined in the invention. The pharmaceutical compositions comprising these compounds and the use of the compounds for treating hepatitis C virus (HCV) infection are also provided.

TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION

Tetracyclic indole derivatives of formula (I), pharmaceutically acceptable salts and the pharmaceutical compositions thereof are provided, wherein A, A', G, R1, R15, U, V, V, W, W, X, X', Y, Y' are as defined in the invention. Use of these derivatives for treating hepatitis C virus (HCV) infection is also provided.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.

FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Fused Tetracycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', B, G, R1, U, V, W, W', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprising at least one Fused Tetracycle Derivative, and methods of using the Fused Tetracycle Derivatives for treating or preventing HCV infection in a patient.

FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention discloses novel Fused Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', W, W', X, X', Y and Y' are as defined herein. The present invention also discloses compositions comprising at least one Fused Tetracyclic Heterocycle Compound, and methods of using the Fused Tetracyclic Heterocycle Compounds for treating or preventing HCV infection in a patient.

PYRROLOTRIAZINE KINASE INHIBITORS

The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.

A concise synthesis of (2S,4R)- and (2S,4S)-4-methylglutamic acid

A concise, multi-gram scale method for producing the bioactive and enantiomerically pure epimers, (2S,4R)- and (2S,4S)-glutamic acids, in a single synthetic scheme is described.

(S)-Ethyl 4,4-dimethyl pyroglutamate as a new 'quat' chiral auxiliary in aldol condensations

Enolates I, derived from the N-propionyl derivative of the 'quat' chiral auxiliary (S)-ethyl 4,4-dimethyl pyroglutamate 4 undergo highly stereoselective aldol reactions, which upon hydrolysis and removal of the chiral auxiliary yields the (2R,3R)-3-hydrox